Literature DB >> 25142726

Sub-inhibitory concentrations of antifungals suppress hemolysin activity of oral Candida albicans and Candida tropicalis isolates from HIV-infected individuals.

Sukumaran Anil1, Mohamed Hashem, Sajith Vellappally, Shankargouda Patil, H M H N Bandara, L P Samaranayake.   

Abstract

Secretion of hydrolytic enzymes such as hemolysin is considered an important virulence attribute of the opportunistic pathogenic fungus Candida. It is known that Candida spp. isolated from HIV-infected patients produce copious hemolysins. As common antifungal agents may perturb the production of extracellular enzymes, we evaluated the effect of three antifungals nystatin, amphotericin B and fluconazole on the hemolytic activity of Candida albicans and Candida tropicalis isolates from HIV-infected individuals. The impact of antimycotics on hemolytic activity was assessed by a previously described in vitro plate assay, after exposing ten isolates each of C. albicans and C. tropicalis recovered from HIV-infected individuals to sub-minimum inhibitory concentrations (sub-MIC) of nystatin, amphotericin B and fluconazole. All Candida isolates showed a significant reduction in hemolytic activity. The reduction was highest for amphotericin B-exposed C. albicans and C. tropicalis followed by nystatin and fluconazole. The effect of antimycotics was more pronounced on the hemolytic activity of C. tropicalis compared to that of C. albicans. Commonly used antifungal agents significantly suppress hemolysin activity of Candida species. This implies that the antifungals, in addition to their lethality, may modulate key virulence attributes of the yeast. The clinical relevance of this phenomenon in HIV disease and other similar pathologies remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25142726     DOI: 10.1007/s11046-014-9802-0

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  54 in total

1.  Increased expression of virulence attributes in oral Candida albicans isolates from human immunodeficiency virus-positive individuals.

Authors:  Arati Mane; Shraddha Gaikwad; Shilpa Bembalkar; Arun Risbud
Journal:  J Med Microbiol       Date:  2011-09-29       Impact factor: 2.472

2.  In vitro differential activity of phospholipases and acid proteinases of clinical isolates of Candida.

Authors:  Aurean D'Eça Júnior; Anderson França Silva; Fernanda Costa Rosa; Sílvio Gomes Monteiro; Patrícia de Maria Silva Figueiredo; Cristina de Andrade Monteiro
Journal:  Rev Soc Bras Med Trop       Date:  2011 May-Jun       Impact factor: 1.581

3.  The epidemiology of hematogenous candidiasis caused by different Candida species.

Authors:  D Abi-Said; E Anaissie; O Uzun; I Raad; H Pinzcowski; S Vartivarian
Journal:  Clin Infect Dis       Date:  1997-06       Impact factor: 9.079

4.  Evaluation of the modified API 20C system for identification of clinically important yeasts.

Authors:  W J Buesching; K Kurek; G D Roberts
Journal:  J Clin Microbiol       Date:  1979-05       Impact factor: 5.948

5.  Phospholipase B enzyme expression is not associated with other virulence attributes in Candida albicans isolates from patients with human immunodeficiency virus infection.

Authors:  Y H Samaranayake; R S Dassanayake; J Ams Jayatilake; B Pk Cheung; J Yy Yau; K Ws Yeung; L P Samaranayake
Journal:  J Med Microbiol       Date:  2005-06       Impact factor: 2.472

6.  Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance.

Authors:  J Chandra; D M Kuhn; P K Mukherjee; L L Hoyer; T McCormick; M A Ghannoum
Journal:  J Bacteriol       Date:  2001-09       Impact factor: 3.490

7.  Virulence Factors and Anti Fungal Sensitivity Pattern of Candida Sp. Isolated from HIV and TB Patients.

Authors:  Nachimuthu Ramesh; Maruthupandian Priyadharsini; Chettipalayam Samiappan Sumathi; Velramar Balasubramanian; Janarthanam Hemapriya; Rajesh Kannan
Journal:  Indian J Microbiol       Date:  2011-04-09       Impact factor: 2.461

8.  Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program.

Authors:  Rana A Hajjeh; Andre N Sofair; Lee H Harrison; G Marshall Lyon; Beth A Arthington-Skaggs; Sara A Mirza; Maureen Phelan; Juliette Morgan; Wendy Lee-Yang; Meral A Ciblak; Lynette E Benjamin; Laurie Thomson Sanza; Sharon Huie; Siew Fah Yeo; Mary E Brandt; David W Warnock
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

9.  Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).

Authors:  Olivier Leroy; Jean-Pierre Gangneux; Philippe Montravers; Jean-Paul Mira; François Gouin; Jean-Pierre Sollet; Jean Carlet; Jacques Reynes; Michel Rosenheim; Bernard Regnier; Olivier Lortholary
Journal:  Crit Care Med       Date:  2009-05       Impact factor: 7.598

10.  In-vitro proteinase production by oral Candida albicans isolates from individuals with and without HIV infection and its attenuation by antimycotic agents.

Authors:  T Wu; L P Samaranayake; B Y Cao; J Wang
Journal:  J Med Microbiol       Date:  1996-04       Impact factor: 2.472

View more
  4 in total

Review 1.  How much do we know about hemolytic capability of pathogenic Candida species?

Authors:  Márcia C Furlaneto; Helena P Góes; Hugo F Perini; Renan C Dos Santos; Luciana Furlaneto-Maia
Journal:  Folia Microbiol (Praha)       Date:  2018-01-15       Impact factor: 2.099

2.  Impact of brief exposure to antifungal agents on the post-antifungal effect and hemolysin activity of oral Candida albicans.

Authors:  Arjuna Nishantha Ellepola; Rana Khajah; Sumedha Jayatilake; Lakshman Samaranayake; Prem Sharma; Zia Khan
Journal:  J Appl Oral Sci       Date:  2015 Jul-Aug       Impact factor: 2.698

Review 3.  An Update on Candida tropicalis Based on Basic and Clinical Approaches.

Authors:  Diana L Zuza-Alves; Walicyranison P Silva-Rocha; Guilherme M Chaves
Journal:  Front Microbiol       Date:  2017-10-13       Impact factor: 5.640

4.  Lactoferrin Is Broadly Active against Yeasts and Highly Synergistic with Amphotericin B.

Authors:  Kenya E Fernandes; Kerry Weeks; Dee A Carter
Journal:  Antimicrob Agents Chemother       Date:  2020-04-21       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.